POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
130 hedge funds and large institutions have $571M invested in POINT Biopharma Global Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 16 closing their positions.
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
25% more capital invested
Capital invested by funds: $455M → $571M (+$116M)
13% more funds holding
Funds holding: 115 → 130 (+15)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
90% less call options, than puts
Call options by funds: $70K | Put options by funds: $679K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$11.1M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$8.48M |
| 3 |
BlackRock
New York
|
+$7.65M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$5.92M |
| 5 |
JP Morgan Chase
New York
|
+$5.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$21.7M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$16.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.5M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$6.52M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.47M |
PNT Hedge Fund Activity: Q2 2023 in Review
130 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q2 2023, worth a combined $571M — up 25% from $455M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new PNT positions and 16 closed out — a net gain of 15 holders — while 49 added to existing stakes and 32 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $11.1M. The largest seller was Rubric Capital Management (New York), cutting an estimated $21.7M.
- 130 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q2 2023, up from 115 in Q1 2023.
- Funds reported $571M of POINT Biopharma Global Inc. Common Stock stock for Q2 2023, up 25% quarter-over-quarter.
- 31 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q2 2023 and 16 closed out, a net change of +15 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q2 2023 was Bellevue Group, an estimated $11.1M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q2 2023 was Rubric Capital Management (New York), an estimated $21.7M sold.
Based on aggregated 13F filings for Q2 2023.